Assessing the Effectiveness of Ikshvakubeejadi Yonivarti in Treating Secondary Amenorrhea (Anartava): A Clinical Study

A Clinical trial to evaluate the effect of Ikshvakubeejadi Yonivarti in Anartava (Secondary Amenorrhoea) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075017

Enrollment

Registered

2024-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N911- Secondary amenorrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Married woman aged 21-45 years Secondary Amenorrhea Low, high, normal FSH level and LH level Hypothyroidism, Increased Prolactin levels

Exclusion criteria

Exclusion criteria: Pregnancy HIV, HBsAg, VDRL positive patients Diagnosed case of HTN, Diabetes Mellitus Anatomical abnormalities

Design outcomes

Primary

Measure	Time frame
Restoration of Menstrual Cycle: The primary outcome will be the proportion of participants who experience the restoration of their menstrual cycle within a specified period (e.g., 3 months) of initiating treatment with Ikshvakubeejadi Yonivarti. Restoration is defined as the resumption of menstrual bleeding at least once within the study period, with cycles occurring at intervals that are within the normal range for menstruation (e.g., every 21 to 35 days).Timepoint: 7 consecutive days in each month for 3 consecutive months	—

Measure

Time frame

Restoration of Menstrual Cycle: The primary outcome will be the proportion of participants who experience the restoration of their menstrual cycle within a specified period (e.g., 3 months) of initiating treatment with Ikshvakubeejadi Yonivarti. Restoration is defined as the resumption of menstrual bleeding at least once within the study period, with cycles occurring at intervals that are within the normal range for menstruation (e.g., every 21 to 35 days).Timepoint: 7 consecutive days in each month for 3 consecutive months

—

Secondary

Measure	Time frame
Cycle Regularity: Improvement in the regularity of menstrual cycles (e.g., transition from irregular to regular cycles). Menstrual Flow: Changes in the volume and duration of menstrual flow once menstruation resumes. Hormone Profiles: Changes in key reproductive hormones (e.g., FSH, LH, estrogen, progesterone) as measured through blood tests. Ovulation Detection: Frequency of ovulation, assessed through hormonal assays or ovulation tracking methods. Menstrual Symptoms: Reduction in symptoms associated with secondary amenorrhea, such as mood swings, hot flashes, or vaginal dryness. Quality of Life: Improvement in quality of life scores related to menstrual health and general well-being, assessed through validated questionnaires. Timepoint: 7 consecutive days in each month for 3 consecutive months	—

Measure

Time frame

Cycle Regularity: Improvement in the regularity of menstrual cycles (e.g., transition from irregular to regular cycles). Menstrual Flow: Changes in the volume and duration of menstrual flow once menstruation resumes. Hormone Profiles: Changes in key reproductive hormones (e.g., FSH, LH, estrogen, progesterone) as measured through blood tests. Ovulation Detection: Frequency of ovulation, assessed through hormonal assays or ovulation tracking methods. Menstrual Symptoms: Reduction in symptoms associated with secondary amenorrhea, such as mood swings, hot flashes, or vaginal dryness. Quality of Life: Improvement in quality of life scores related to menstrual health and general well-being, assessed through validated questionnaires. Timepoint: 7 consecutive days in each month for 3 consecutive months

—

Countries

India

Contacts

Public ContactSamprati Jain

Sri Jayendra Saraswathi Ayurveda College and Hospital, Chennai

drlrathnakar@sjsach.org.in9840340826

Outcome results